MA29345B1 - Nouvelles formes polymorphes de rifaximine, leurs procedes de preparation et leur utilisation en medecine. - Google Patents

Nouvelles formes polymorphes de rifaximine, leurs procedes de preparation et leur utilisation en medecine.

Info

Publication number
MA29345B1
MA29345B1 MA30245A MA30245A MA29345B1 MA 29345 B1 MA29345 B1 MA 29345B1 MA 30245 A MA30245 A MA 30245A MA 30245 A MA30245 A MA 30245A MA 29345 B1 MA29345 B1 MA 29345B1
Authority
MA
Morocco
Prior art keywords
rifaximin
rifaximine
preparing
methods
medicine
Prior art date
Application number
MA30245A
Other languages
English (en)
Inventor
Giuseppe Claudio Viscomi
Manuela Campana
Donatella Confortini
Maria Miriam Barbanti
Dario Braga
Original Assignee
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34934045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29345(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa
Publication of MA29345B1 publication Critical patent/MA29345B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/21—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a nitrogen atom directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D499/44—Compounds with an amino radical acylated by carboxylic acids, attached in position 6
    • C07D499/48—Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical
    • C07D499/58—Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical substituted in alpha-position to the carboxamido radical
    • C07D499/64—Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical substituted in alpha-position to the carboxamido radical by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

NOUVELLES FORMES POLYMORPHES DE RIFAXIMINE, LEURS PROCEDES DE PREPARATION ET LEUR UTILISATION EN MEDECINE Des formes cristallines polymorphes de l'antibiotique rifaximine (INN), appelées rifaximine (delta); et rifaximine (ipsilon), pouvant être utilisées pour fabriquer des préparations médicinales contenant de la rifaximine pour un usage oral et topique, et obtenues au moyen d'un procédé de cristallisation effectué en dissolvant à chaud la rifaximine à l'état brut dans de l'alcool éthylique et en provoquant la cristallisation du produit par ajout d'eau à une température déterminée et pendant un laps de temps déterminé, suivi par un séchage effectué dans des conditions contrôlées jusqu'à atteindre la teneur en eau voulue dans le produit final.
MA30245A 2005-03-03 2007-09-26 Nouvelles formes polymorphes de rifaximine, leurs procedes de preparation et leur utilisation en medecine. MA29345B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05004695.2A EP1698630B1 (fr) 2005-03-03 2005-03-03 Nouvelles formes polymorphes du rifaximin, procédés pour leur préparation et leur utilisation en tant que médicaments

Publications (1)

Publication Number Publication Date
MA29345B1 true MA29345B1 (fr) 2008-03-03

Family

ID=34934045

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30245A MA29345B1 (fr) 2005-03-03 2007-09-26 Nouvelles formes polymorphes de rifaximine, leurs procedes de preparation et leur utilisation en medecine.

Country Status (27)

Country Link
US (9) US8193196B2 (fr)
EP (1) EP1698630B1 (fr)
JP (2) JP5737825B2 (fr)
KR (1) KR100885755B1 (fr)
CN (1) CN1900077B (fr)
AU (1) AU2006222312B8 (fr)
BR (1) BRPI0608073A8 (fr)
CA (1) CA2594789C (fr)
DK (1) DK1698630T3 (fr)
ES (1) ES2522895T3 (fr)
HR (1) HRP20070433B1 (fr)
IL (1) IL184694A0 (fr)
MA (1) MA29345B1 (fr)
MD (1) MD4081G2 (fr)
ME (1) ME00272B (fr)
MX (1) MX2007010742A (fr)
NO (1) NO342197B1 (fr)
NZ (1) NZ556737A (fr)
PL (1) PL1698630T3 (fr)
PT (1) PT1698630E (fr)
RS (1) RS54570B1 (fr)
RU (1) RU2397985C2 (fr)
SI (1) SI1698630T1 (fr)
TN (1) TNSN07292A1 (fr)
UA (1) UA89809C2 (fr)
WO (1) WO2006094662A1 (fr)
ZA (1) ZA200707397B (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7906542B2 (en) 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
PT1698630E (pt) * 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
EP2069363B1 (fr) 2006-09-22 2013-03-20 Cipla Ltd. Rifaximine sous une forme amorphe
ITMI20071241A1 (it) * 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
US8486956B2 (en) * 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
US8067429B2 (en) * 2008-02-25 2011-11-29 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
US11779571B2 (en) 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
PT2252148T (pt) 2008-02-26 2020-01-23 Salix Pharmaceuticals Ltd Métodos de tratamento da síndrome do intestino irritável
HRP20140939T1 (hr) 2008-05-07 2014-11-21 Salix Pharmaceuticals, Ltd. Davanje preparata za äśišä†enje crijeva i antibiotika za lijeäśenje bolesti crijeva
AU2009297562B2 (en) 2008-09-26 2015-04-23 Alfasigma S.P.A. Agent for preventing and/or treating functional gastrointestinal disorder
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US12285414B2 (en) 2008-10-02 2025-04-29 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
BRPI0920465A2 (pt) 2008-10-02 2018-03-20 Salix Pharmaceuticals, Inc. metodo de tratamento de encefalopatia hepática
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US8916193B2 (en) 2008-12-10 2014-12-23 Cipla Limited Rifaximin complexes
NZ598671A (en) 2009-09-13 2014-02-28 Salix Pharmaceuticals Ltd Methods for treating irritable bowel syndrome (ibs)
EP2503989A2 (fr) 2009-11-23 2012-10-03 Cipla Limited Composition de mousse topique
US8952159B2 (en) 2009-12-28 2015-02-10 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
AU2011218129A1 (en) 2010-02-18 2012-08-23 Board Of Regents Of The University Of Texas System Methods for treating infection
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
CN101836959A (zh) * 2010-05-20 2010-09-22 山东达因海洋生物制药股份有限公司 一种制备几乎无苦味利福昔明干混悬剂的方法
CA2802874A1 (fr) * 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Formes polymorphiques de rifaximine
SMT202000390T1 (it) 2010-07-12 2020-09-10 Salix Pharmaceuticals Inc Formulazioni di rifaximina e loro usi
WO2012035544A2 (fr) 2010-09-13 2012-03-22 Sequent Scientific Ltd. Nouvelle forme polymorphe de rifaximine et son procédé de préparation
IT1403847B1 (it) 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
WO2012109605A2 (fr) 2011-02-11 2012-08-16 Salix Pharmaceuticals, Ltd. Formes de rifaximine et leurs utilisations
CA2834829A1 (fr) 2011-05-02 2012-11-08 Ranbaxy Laboratories Limited Solvate de dimethylformamide rifaximine
ITMI20110890A1 (it) * 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
WO2013027227A1 (fr) * 2011-07-20 2013-02-28 Ind-Swift Laboratories Limited Nouvelle forme polymorphe i de la rifaximine
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
US20130184302A1 (en) * 2011-11-02 2013-07-18 Enoch Bortey Methods for treating irritable bowel syndrome (ibs) and infections
US9359374B2 (en) 2012-06-13 2016-06-07 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
US9849090B2 (en) 2012-12-12 2017-12-26 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of rifaximin
US20160038468A1 (en) 2013-03-15 2016-02-11 Alfa Wassermann S.P.A. Rifaximin for use in the treating of vaginal infections
US20160047819A1 (en) 2013-03-15 2016-02-18 Alfa Wassermann S.P.A. Method for diagnosing vaginal infections
CN105324109A (zh) 2013-04-12 2016-02-10 意大利阿尔法韦士曼制药公司 Nsaid施用和相关的组合物、方法和系统
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
US20150103715A1 (en) * 2013-10-14 2015-04-16 Qualcomm Incorporated Downlink control format indicator
EP2927235B1 (fr) 2014-03-31 2017-02-08 Euticals S.P.A. Mélange de polymorphes de rifaximine et son utilisation pour la préparation de formulations solides
US9765088B2 (en) 2014-04-19 2017-09-19 Granules India Limited Process for the preparation of rifamycin derivatives
CA2947962C (fr) 2014-05-04 2024-01-16 Salix Pharmaceuticals, Inc. Microbiote du syndrome du colon irritable et utilisations associees
AU2015260837B2 (en) 2014-05-12 2019-02-28 Alfasigma S.P.A. New solvated crystal form of rifaximin, production, compositions and uses thereof
EP2982764A1 (fr) 2014-08-05 2016-02-10 ALFA WASSERMANN S.p.A. Identification de bactérie vaginale
EP3325100A4 (fr) 2015-07-17 2019-02-20 Memorial Sloan-Kettering Cancer Center Thérapie combinée utilisant des inhibiteurs de pdk1 et de pi3k
HUE040253T2 (hu) 2016-03-24 2019-02-28 Sandoz Ag Rifaximin alfa&deltát tartalmazó gyógyászati készítmény
HUE044432T2 (hu) 2016-03-24 2019-10-28 Sandoz Ag Rifaximin alfá-t tartalmazó, hosszan eltartható kompozíció
US9988398B2 (en) 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
CA3038312A1 (fr) 2016-09-30 2018-04-05 Salix Pharmaceuticals, Inc. Formes de dispersions solides de rifaximine
CA3013161C (fr) 2017-04-26 2020-03-24 Sandoz Ag Forme de dosage orale comprenant du rifaximine sous forme beta
IT201700091912A1 (it) * 2017-08-08 2019-02-08 Biofer Spa Nuove pirido-imidazo rifamicine
RU2020102511A (ru) 2017-06-26 2021-07-27 Биофер С.П.А. Соединения пиридо-имидазо рифамицина в качестве антибактериального средства
CA3142214A1 (fr) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Utilisation de methylnaltrexone et de rifaximine pour le traitement d'une permeabilite intestinale accrue ou de troubles associes
MX427410B (es) 2019-09-24 2025-10-13 Bausch Health Ireland Ltd Formulaciones liquidas de rifaximina
WO2021191312A1 (fr) 2020-03-24 2021-09-30 Bausch Health Ireland Limited Procédés de traitement de la covid-19 avec de la rifaximine
CA3184054A1 (fr) 2020-06-26 2021-12-30 Jacob Cole Compositions de rifaximine a liberation ciblee
KR20230088761A (ko) * 2020-10-13 2023-06-20 베링거 인겔하임 인터내셔날 게엠베하 재가공하는 방법
US20230398102A1 (en) 2020-10-29 2023-12-14 Bausch Health Ireland Limited Rifaximin liquid formulations for use inthe treatment of sickle cell disease

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2043847A1 (fr) 1969-05-30 1971-02-19 Takeda Chemical Industries Ltd
CH571064A5 (en) 1973-03-01 1975-12-31 Archifar Ind Chim Trentino Recovery of rieamycin from broths - by oxidn to an insol form
US4267274A (en) 1973-04-26 1981-05-12 Gruppo Lepetit S.P.A. Streptomyces mediterranei mutant capable of production of rifamycin B
GB1470426A (en) 1974-08-30 1977-04-14 Lepetit Spa Rifamycins
IT1154655B (it) * 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
CA1215976A (fr) 1984-05-15 1986-12-30 Vincenzo Cannata Nouvelle methode pour la synthese d'imidazorifamycines
IT1199374B (it) * 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
IT1199413B (it) 1984-09-26 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
US5356625A (en) 1986-08-28 1994-10-18 Enzacor Properties Limited Microgranular preparation useful in the delivery of biologically active materials to the intestinal regions of animals
GB8816620D0 (en) 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
CA2082809C (fr) 1990-06-29 1995-10-17 Marino Nebuloni Preparation cristalline pure de rifapentine
IT1253711B (it) 1991-12-17 1995-08-23 Alfa Wassermann Spa Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali
IT1264494B1 (it) 1993-03-23 1996-09-24 Alfa Wassermann Spa Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter
US6271001B1 (en) 1995-03-23 2001-08-07 Bio Polymers Pty. Ltd. Cultured plant cell gums for food, pharmaceutical, cosmetic and industrial applications
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
JP4195728B2 (ja) 1996-10-16 2008-12-10 ナポ ファーマシューティカルズ，インコーポレーテッド プロアントシアニジンポリマー止瀉組成物の腸溶製剤
IT1290679B1 (it) 1997-02-14 1998-12-10 Alfa Wassermann Spa Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
US20030059471A1 (en) 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US20030157174A1 (en) 2000-03-23 2003-08-21 Takayuki Tsukuda Enteric granular preparations of hardly water soluble drugs characterized by containing water-repellent component
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
CA2426393C (fr) * 2000-10-31 2012-05-29 Ciba Specialty Chemicals Holding Inc. Formes cristallines de chlorhydrate de venlafaxine
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
DK1383512T3 (da) 2001-05-03 2004-11-15 Farmigea Spa Anvendelse af sucralfat til behandling af cervikal erosion
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
WO2003101460A1 (fr) 2002-06-03 2003-12-11 Cac Corporation Preparations a usage externe pour le traitement de la dermatite
RU2223764C1 (ru) * 2002-07-16 2004-02-20 Закрытое акционерное общество "АИП-Наука" Способ получения липосомальной формы рифампицина
CZ13908U1 (cs) 2003-10-08 2004-01-05 Cpn Spol. S R.O. Kosmetický přípravek s vysokomolekulární antioxidační složkou
US7906542B2 (en) 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7923553B2 (en) 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US20080262024A1 (en) 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US20050196418A1 (en) 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US20050256118A1 (en) * 2004-05-12 2005-11-17 Altenbach Robert J Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
BRPI0513417A (pt) 2004-07-16 2008-05-06 Cipla Ltd composição farmacêutica estável, usos de um poliol, e de uma composição, processo para preparar uma composição farmacêutica, e, método para tratar uma condição responsiva à administração de uma anti-histamina
US8003118B2 (en) 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
US20060210483A1 (en) 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
US20060210492A1 (en) 2005-03-02 2006-09-21 Kodsi Robert E Use of rifaximin for treatment and prevention of periodontal conditions
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
ITBO20050388A1 (it) 2005-06-06 2006-12-07 Alfa Wassermann Spa Formulazione mucoadesive utili in dispositivi medici in preparazioni farmaceutiche
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
EP2069363B1 (fr) 2006-09-22 2013-03-20 Cipla Ltd. Rifaximine sous une forme amorphe
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
ES2798253T3 (es) 2007-07-06 2020-12-10 Lupin Ltd Composiciones farmacéuticas de rifaximina
JP5755878B2 (ja) 2007-07-06 2015-07-29 ルパン リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ リファキシミンの薬剤組成物
WO2009008006A2 (fr) 2007-07-06 2009-01-15 Lupin Limited Compositions pharmaceutiques d'administration gastro-intestinale de médicaments
JP2010259452A (ja) * 2007-08-21 2010-11-18 Konica Minolta Medical & Graphic Inc 画像診断支援装置及び画像診断支援方法
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
WO2009047801A1 (fr) 2007-10-10 2009-04-16 Lupin Limited Combinaisons thérapeutiques et compositions pour le traitement de troubles gastro-intestinaux
US8067429B2 (en) 2008-02-25 2011-11-29 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
PT2252148T (pt) 2008-02-26 2020-01-23 Salix Pharmaceuticals Ltd Métodos de tratamento da síndrome do intestino irritável
HRP20140939T1 (hr) 2008-05-07 2014-11-21 Salix Pharmaceuticals, Ltd. Davanje preparata za äśišä†enje crijeva i antibiotika za lijeäśenje bolesti crijeva
BRPI0920465A2 (pt) 2008-10-02 2018-03-20 Salix Pharmaceuticals, Inc. metodo de tratamento de encefalopatia hepática
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US20100317681A1 (en) 2009-06-15 2010-12-16 Salix Pharmaceuticals, Ltd. Modulation of systemic exposure to rifaximin
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
WO2010044093A1 (fr) 2008-10-16 2010-04-22 Strides Arcolab Limited Préparations contenant de la rifaximine
US8916193B2 (en) 2008-12-10 2014-12-23 Cipla Limited Rifaximin complexes
JP5276505B2 (ja) * 2009-04-06 2013-08-28 株式会社ユニバーサルエンターテインメント 遊技機
IT1397617B1 (it) 2009-04-20 2013-01-18 Alfa Wassermann Spa Nuovi derivati della rifamicina
MX2011013427A (es) 2009-06-15 2012-04-20 Salix Pharmaceuticals Ltd Modulacion de exposicion sistemica a rifaximina.
NZ598671A (en) 2009-09-13 2014-02-28 Salix Pharmaceuticals Ltd Methods for treating irritable bowel syndrome (ibs)
EP2493471B1 (fr) 2009-10-26 2019-11-27 Thomas Julius Borody Nouvelle polythérapie gastro-résistante
RU2012121599A (ru) 2009-10-27 2013-12-10 Люпин Лимитед Твердая дисперсия рифаксимина
WO2011061748A1 (fr) 2009-11-19 2011-05-26 Strides Arcolab Limited Prémélange à base de rifaximine
BR112012012315A2 (pt) 2009-11-23 2018-10-16 Cipla Ltd composição farmacêutica para administração retal tópica na forma de espuma, uso de uma composição farmacêutica, método para tratamento, prevenção ou alívio de um dustúrbio no reto, cólon, íleo terminal ou anus, processo para fabricação de uma composição farmacêutica contendo rifaximina, uso de silicone e dispensador para composição farmacêutica
EP2503989A2 (fr) 2009-11-23 2012-10-03 Cipla Limited Composition de mousse topique
US8952159B2 (en) 2009-12-28 2015-02-10 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
CN101773465B (zh) 2010-01-19 2012-11-07 南京泛太化工医药研究所 以氨基酸为稳定剂的聚合物胶束载药系统
AU2011218129A1 (en) 2010-02-18 2012-08-23 Board Of Regents Of The University Of Texas System Methods for treating infection
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
AU2011225810B2 (en) 2010-03-10 2014-11-06 Lupin Limited Rifaximin ready-to-use suspension
ES2682051T3 (es) 2010-04-23 2018-09-18 The Procter & Gamble Company Composición detergente
WO2011153444A1 (fr) 2010-06-03 2011-12-08 Salix Pharmaceuticals, Ltd Nouvelles formes de la rifaximine et leurs utilisations
CA2802874A1 (fr) 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Formes polymorphiques de rifaximine
SMT202000390T1 (it) 2010-07-12 2020-09-10 Salix Pharmaceuticals Inc Formulazioni di rifaximina e loro usi
CN103221032A (zh) 2010-09-13 2013-07-24 西普拉有限公司 药物组合物
WO2012035544A2 (fr) 2010-09-13 2012-03-22 Sequent Scientific Ltd. Nouvelle forme polymorphe de rifaximine et son procédé de préparation
IT1403847B1 (it) 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
WO2012060675A1 (fr) 2010-11-05 2012-05-10 Interquim, S.A. De C.V. Procédé de préparation de rifaximine amorphe
WO2012076832A1 (fr) 2010-12-09 2012-06-14 Cipla Limited Suppositoires contenant de la rifaximine
WO2012109605A2 (fr) 2011-02-11 2012-08-16 Salix Pharmaceuticals, Ltd. Formes de rifaximine et leurs utilisations
CA2834829A1 (fr) 2011-05-02 2012-11-08 Ranbaxy Laboratories Limited Solvate de dimethylformamide rifaximine
ITMI20110890A1 (it) 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
WO2012155981A1 (fr) 2011-05-19 2012-11-22 Friulchem Spa Nouveau procédé pour la synthèse de rifaximine et nouvelle forme pseudo-cristalline de rifaximine obtenue au moyen de celui-ci
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
US20130184302A1 (en) 2011-11-02 2013-07-18 Enoch Bortey Methods for treating irritable bowel syndrome (ibs) and infections
AU2013212008A1 (en) 2012-01-25 2014-07-10 Alfa Wassermann S.P.A. Rifaximin derivative and uses thereof
JP2013184902A (ja) 2012-03-06 2013-09-19 Aska Pharmaceutical Co Ltd リファキシミン含有結晶
US9359374B2 (en) 2012-06-13 2016-06-07 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
US9849090B2 (en) 2012-12-12 2017-12-26 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of rifaximin
CN105324109A (zh) 2013-04-12 2016-02-10 意大利阿尔法韦士曼制药公司 Nsaid施用和相关的组合物、方法和系统
WO2014186675A1 (fr) 2013-05-17 2014-11-20 Salix Pharmaceuticals, Inc. Procédés d'utilisation de rifaximine dans des balayages de tomographie à émission de positons (pet)
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
ITMI20131307A1 (it) 2013-08-02 2015-02-02 A M S A Anonima Materie Sint & Affini S P A Processo per la preparazione di refaximina k
EP2927235B1 (fr) 2014-03-31 2017-02-08 Euticals S.P.A. Mélange de polymorphes de rifaximine et son utilisation pour la préparation de formulations solides
US9765088B2 (en) 2014-04-19 2017-09-19 Granules India Limited Process for the preparation of rifamycin derivatives
AU2015260837B2 (en) 2014-05-12 2019-02-28 Alfasigma S.P.A. New solvated crystal form of rifaximin, production, compositions and uses thereof
WO2016063289A2 (fr) 2014-10-22 2016-04-28 Strides Arcolab Limited Compositions de comprimé pharmaceutique comprenant de la rifaximine
WO2017021975A1 (fr) 2015-08-06 2017-02-09 Msn Laboratories Private Limited Procédé de préparation de formes cristallines de rifaximine
HUE040253T2 (hu) 2016-03-24 2019-02-28 Sandoz Ag Rifaximin alfa&deltát tartalmazó gyógyászati készítmény
HUE044432T2 (hu) 2016-03-24 2019-10-28 Sandoz Ag Rifaximin alfá-t tartalmazó, hosszan eltartható kompozíció
US9988398B2 (en) 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
WO2018158646A1 (fr) 2017-03-02 2018-09-07 Granules India Limited Forme cristalline de la rifaximine
WO2018178777A1 (fr) 2017-03-31 2018-10-04 Granules India Limited Procédé de préparation d'une forme cristalline de rifaximine
CA3013161C (fr) 2017-04-26 2020-03-24 Sandoz Ag Forme de dosage orale comprenant du rifaximine sous forme beta
RU2020102511A (ru) 2017-06-26 2021-07-27 Биофер С.П.А. Соединения пиридо-имидазо рифамицина в качестве антибактериального средства

Also Published As

Publication number Publication date
US20220119403A1 (en) 2022-04-21
WO2006094662A1 (fr) 2006-09-14
NZ556737A (en) 2011-11-25
RS20070364A (sr) 2009-01-22
PL1698630T3 (pl) 2014-12-31
US9271968B2 (en) 2016-03-01
US8741904B2 (en) 2014-06-03
EP1698630A8 (fr) 2006-10-25
JP2013216710A (ja) 2013-10-24
US20150073007A1 (en) 2015-03-12
ES2522895T3 (es) 2014-11-19
ZA200707397B (en) 2009-03-25
IL184694A0 (en) 2007-12-03
US20120245355A1 (en) 2012-09-27
MEP34408A (en) 2011-02-10
US10703763B2 (en) 2020-07-07
SI1698630T1 (sl) 2015-01-30
EP1698630B1 (fr) 2014-09-03
RS54570B1 (sr) 2016-06-30
PT1698630E (pt) 2014-09-15
EP1698630A1 (fr) 2006-09-06
MD20070265A (en) 2008-05-31
CN1900077A (zh) 2007-01-24
KR20060096242A (ko) 2006-09-11
US20200277301A1 (en) 2020-09-03
US8518949B2 (en) 2013-08-27
BRPI0608073A2 (pt) 2009-11-03
CA2594789C (fr) 2010-09-14
CA2594789A1 (fr) 2006-09-14
US20160362419A1 (en) 2016-12-15
KR100885755B1 (ko) 2009-02-26
RU2007136430A (ru) 2009-04-10
TNSN07292A1 (en) 2008-12-31
BRPI0608073A8 (pt) 2017-12-26
US20130310410A1 (en) 2013-11-21
HK1096396A1 (en) 2007-06-01
NO20074988L (no) 2007-11-30
HRP20070433B1 (hr) 2015-02-27
US8193196B2 (en) 2012-06-05
US20180291032A1 (en) 2018-10-11
JP5737825B2 (ja) 2015-06-17
MD4081F2 (en) 2010-12-31
UA89809C2 (uk) 2010-03-10
US20090130201A1 (en) 2009-05-21
JP2008531623A (ja) 2008-08-14
DK1698630T3 (da) 2014-12-08
AU2006222312B2 (en) 2011-11-03
MD4081G2 (ro) 2011-07-31
HRP20070433A2 (en) 2007-11-30
MX2007010742A (es) 2007-09-12
CN1900077B (zh) 2012-04-11
ME00272B (fr) 2011-05-10
US20200002350A1 (en) 2020-01-02
AU2006222312B8 (en) 2011-11-17
RU2397985C2 (ru) 2010-08-27
AU2006222312A1 (en) 2006-09-14
NO342197B1 (no) 2018-04-16

Similar Documents

Publication Publication Date Title
MA27069A1 (fr) FORMES POLYMORPHES DE RIFAXIMIN, PROCEDES POUR LEUR PRODUCTION ET USAGE DE MeME DANS LES PREPARATIONS MEDICINALES
JP7745892B2 (ja) Ｎ４－ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途
KR100839265B1 (ko) 치환된 티오아세트아미드
ES2811342T3 (es) Antagonista de receptores de endotelina y angiotensina II de bifenilsulfonamida para tratar glomeruloesclerosis y nefropatía inducida por IgA
AU2002213393B2 (en) Biaryl compounds as serine protease inhibitors
US8829197B2 (en) Salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
US20050203122A1 (en) Benzenesulfonic acid salts of clopidogrel, methods for preparing same, and pharmaceutical formulations thereof
FI89598B (fi) Foerfarande foer framstaellning av vattenfritt, kristallint natriumsalt av 5-klor-3-(2-tenoyl)-2-oxindol-1-karboxamid som laempar sig foer anvaendning som analgetiskt eller antiinflammatoriskt medel
MXPA04004464A (es) Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
WO1999052525A1 (fr) Thienylazolylalcoxyethanamines, leur preparation et leur application en tant que medicaments
WO2013017974A1 (fr) Compositions et méthodes pour le traitement de troubles neuromusculaires et de maladies neurodégénératives
NO20074988L (no) Nye polymorfe former av rifaximin, prosesser for deres fremstilling og anvendelse derav i medisin
JP5142448B2 (ja) ４−［２−［１−（２−エトキシエチル）−１Ｈ−ベンズイミダゾール−２−イル］−１−ピペリジニル］エチル］−α，α−ジメチルベンゼノ酢酸の多形体
EP0579681A1 (fr) Monohydrate d'hydrochlorure de tiagabine cristalline, sa preparation et son utilisation
FI93112C (fi) Menetelmä uusien kinolyylioksatsol-2-onien valmistamiseksi, jotka ovat käyttökelpoisia proteiinikinaasi C:n inhibiittoreina
CN1042225C (zh) 新的取代的异噁唑衍生物的制备方法
ES2277960T3 (es) Base libre de la amlodipina.
ES2201440T3 (es) S-2'-(2-(1-metil-2-piperidil)etil)cinnamanilida como antagonista del receptor 5-ht2.
CN116496205A (zh) 一种卡瑞斯汀的盐及其用途
ES2241574T3 (es) Sistemas policiclicos de tiazol y su uso como anorexicos.
CA2647163C (fr) Inhibiteurs du facteur d'inhibition de la migration des macrophages modifies
FR2753970A1 (fr) Derives de n-(benzothiazol-2-yl) piperidine-1-ethanamine, leur preparation et leur application en therapeutique
CN102443005A (zh) 查尔酮的螺杂环类化合物及其用途
JPH08512314A (ja) 新規な（１−フェニル−１−ヘテロサイクリル）メタノールおよび（１−フェニル−１−ヘテロサイクリル）メチルアミン誘導体
ES2246224T3 (es) Sistemas policiclicos de 2-amino-dihidrotiazol, procedimiento para su preparacion y su empleo como medicamentos.